

REMARKS

Claims 41-59 are pending in the subject application. In the Restriction Requirement, the Examiner required restriction under 35 U.S.C. §§ 121 and 372 between:

- Group I, claim(s) 41-49, drawn to a method of identifying and quantifying tumor-associated peptides.
- Group II, claim(s) 50 -52, drawn to peptides of SEQ ID Nos 1-36, pharmaceutical, and composition.
- Group III, claim(s) 53-55, drawn to nucleic acid, vector, cell.
- Group IV, claim(s) 56, drawn to method of formulating vaccine.
- Group V, claim(s) 57, drawn to diagnosis method.
- Group VI, claim(s) 58 drawn to treatment method.
- Group VII, claim(s) 59, drawn to electronic storage medium.

The Examiner further required election of a single species (one of the thirty-six SEQ ID Nos 1-36) to which the claims shall be restricted if no generic claim is finally held to be allowable, and noted that the reply must identify the claims readable on the elected species, including any claims subsequently added.

The Applicants elect to prosecute the Group I claims (41-49), drawn to a method of identifying and quantifying tumor-associated peptides, without traverse. If no generic claim is finally held to be allowable, the Applicants further elect the species SEQ ID NO:24 (RLAQHITYV).

By this Amendment and Election, the Applicants are withdrawing claims 50-59, consistent with their election of the Group I claims. Further, the Applicants have submitted new claim 60, which is also drawn to a method of identifying and quantifying tumor-associated peptides.

Accordingly, claims 41-49, and 60 are before the Examiner for prosecution. Each of claims 41-49, and 60 are readable on the elected species SEQ ID NO:24.

It is believed that the stated grounds for imposing the Restriction Requirement have been properly addressed. The Office is hereby authorized to charge the requisite fee due upon filing of this paper, and any additional fee owed, to Baker Donelson Bearman Caldwell & Berkowitz, PC, Deposit Account No. 50-4254, referencing docket no. 2912919-006000. If the Examiner determines that a telephone conference with the undersigned would expedite allowance or resolve any further questions, such a conference is invited at the Examiner's convenience.

Respectfully submitted,

**BAKER, DONELSON, BEARMAN,
CALDWELL & BERKOWITZ, P.C.**

DATED: 12 October 2009

/C.G. Moore/

Chester G. Moore, Ph.D.
Reg. No. 53,345

Susan E. McBee
Reg. No. 39294

555 11th Street N.W.
Sixth Floor
Washington, DC 20004
Tel: 202-508-3450
Fax: 202-220-2279
E-Mail: cmoore@bakerdonelson.com